ADA2 and immunodeficiency disease: Similarly, when comparing patients with a hematologic phenotype (with or without concomitant immunodeficiency) (n = 9; 5 missing values) to patients with a vasculopathy phenotype (with or without immunodeficiency) (n = 11; 4 missing values), we found no significant difference in residual ADA2 enzyme activity (Fig. 1B).